About EXIR, INC.
Exir Bio is a biotechnology company focused on improving drug safety evaluation through advanced primate in vitro models that align with the FDA Modernization Act and the 3R principles. The company was founded in 2022 in Silicon Valley and uses New Approach Methods (NAMs) to generate nonhuman primate-derived tissues in vitro.
Generation of nonhuman primate (NHP)-derived tissues in vitroDrug safety evaluation using primate in vitro modelsIn vitro to in vivo translation within the same speciesLong-read sequencing and genomic toxicologyDART (Drug Abuse Resistance Testing) in vitro assaysPrimary cells and specimen analysisAI and computational genomics for primate genomicsStem cell biology and genome engineering
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to EXIR, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.